It is vital to identify the underlying cause of chronic laryngopharyngeal neuropathy

We reviewed, with great interest, the paper entitled "Randomized double blind trial of amitriptyline versus placebo in treatment of chronic laryngopharyngeal neuropathy," by Jang et al. [1]. This is an excellent work. The authors found that subjective laryngopharyngeal symptoms improved in 67% patients of an amitriptyline group and in 44% patients of a placebo group. However, we believe that the inclusion criteria and exclusion criteria were somewhat inappropriate. Also, the measures of clinical outcomes could have been improved.

http://ift.tt/2zpYa2M